Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 1.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 152,359 shares of the medical research company’s stock after selling 2,010 shares during the period. Fisher Asset Management LLC owned 0.08% of Exact Sciences worth $11,272,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC boosted its stake in Exact Sciences by 459.5% during the 4th quarter. Wolff Wiese Magana LLC now owns 414 shares of the medical research company’s stock worth $31,000 after purchasing an additional 340 shares during the period. Able Wealth Management LLC acquired a new stake in Exact Sciences during the 4th quarter worth $45,000. Valley National Advisers Inc. boosted its stake in Exact Sciences by 29.5% during the 3rd quarter. Valley National Advisers Inc. now owns 773 shares of the medical research company’s stock worth $53,000 after purchasing an additional 176 shares during the period. National Bank of Canada FI boosted its stake in Exact Sciences by 30.9% during the 4th quarter. National Bank of Canada FI now owns 848 shares of the medical research company’s stock worth $63,000 after purchasing an additional 200 shares during the period. Finally, Quest Partners LLC purchased a new position in Exact Sciences during the 4th quarter worth $66,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $41.92 on Thursday. The company has a current ratio of 1.64, a quick ratio of 1.45 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $53.57 and a two-hundred day moving average price of $61.28. Exact Sciences Co. has a twelve month low of $41.08 and a twelve month high of $100.77. The company has a market capitalization of $7.74 billion, a P/E ratio of -31.76 and a beta of 1.26.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). Exact Sciences had a negative net margin of 9.48% and a negative return on equity of 7.12%. The firm had revenue of $637.52 million during the quarter, compared to the consensus estimate of $624.95 million. As a group, research analysts expect that Exact Sciences Co. will post -1.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $70.00, for a total transaction of $140,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,787 shares in the company, valued at approximately $5,025,090. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now directly owns 1,156,191 shares of the company’s stock, valued at approximately $69,544,888.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $70.00, for a total transaction of $140,000.00. Following the sale, the executive vice president now directly owns 71,787 shares in the company, valued at $5,025,090. The disclosure for this sale can be found here. In the last three months, insiders sold 5,498 shares of company stock worth $370,105. 1.36% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on EXAS shares. Jefferies Financial Group started coverage on shares of Exact Sciences in a research report on Monday, June 3rd. They set a “buy” rating and a $75.00 price objective for the company. Citigroup cut their price objective on shares of Exact Sciences from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. BTIG Research cut their price objective on shares of Exact Sciences from $85.00 to $80.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Canaccord Genuity Group cut their price objective on shares of Exact Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Finally, William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.07.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.